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ABSTRACT
Lung cancer is the leading cause of cancer-related mortality worldwide. Animal 
models are key in analyzing cancer biology and therapy evaluation.
We here compared relevant non-genetic lung cancer models with regard to tumor 
induction period, incidence, morbidity and mortality rate and the immunological 
composition of primary tumors and the occurrence of tertiary lymphoid organs (TLO): 
(I) intraperitoneal Urethane injection (1g/kg), (II) Lewis lung carcinoma (LLC) cell 
line model (intravenous or subcutaneous), and (III) ex vivo three-dimensional (3D) 
primary cell culture model established from subcutaneously developed LLC-induced 
tumors.
The incidence of Urethane induced lung tumors was 100% in both, C57BL/6 and 
BALB/c strains without morbidity or mortality at twenty weeks after injection. The 
mean size of tumor nodules after Urethane injection was significantly larger in BALB/c 
mice vs. C57BL/6 (p<0.01). Three times of Urethane injection produced significantly 
more tumor nodules in both mouse strains compared to one injection (BALB/c: 
p<0.01; C57BL/6: p<0.05). TLOs were only found in the Urethane-induced model. 
Although the cell line models also showed 100% induction rate, morbidity was high 
due to skin ulceration on the inoculation site and the development of pleural effusions 
in the subcutaneous model and the intravenous model, respectively. Tendencies, but 
no significant differences (p>0.05) could be found in the count of CD4+, CD8+, F4/80+ 
and NKp46+ cells in a tumor nodule among investigated models.
All discussed models provided a high tumor incidence rate. TLOs were exclusively 
found in the Urethane-induced model. No significant difference could be found 
regarding immune cells across models.
INTRODUCTION
Mouse tumor models have been proven to be crucial 
to understand cancer biology and to develop therapeutics 
against cancer [1]. There are, on the one hand, genetically 
engineered mouse models available when tumors develop 
upon induction of oncogenes or through the suppression 
of tumor suppressor genes [2, 3]. On the other hand, 
there are conventional lung cancer models using xeno- 
or allotransplantation of established cancer cell lines or 
carcinogens for the induction of cancer, either orthotopic 
in the original organ or heterotopic outside the organ [4]. 
The latter models are among the most frequently used 
models for the research of cancer mechanism and for 
preclinical drug development [1, 2].
One of those aforementioned mouse models is the 
chemical-induced cancer model. When using a susceptible 
mouse strain [5, 6], Urethane as a carcinogen induces 
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lung cancer [7]. Urethane is known to activate the Kras 
proto-oncogene in early stages of murine lung tumor 
development and qualifies as such as an appropriate study 
model of Ras-driven lung cancer [8, 9]. Another lung 
cancer model employs the injection of lung cancer cell 
lines intravenously into a mouse to induce tumor growth 
either orthotopically or heterotopically. Both, human 
cancer cells and murine cancer cells can be employed in 
this model. Patient xenograft models using human cancer 
cells are usually applied to predict the drug response in 
patients [10]. Apart from these in vivo models, a three 
dimensional (3D) ex vivo/in vitro cell culture model is 
available as an emerging model technic with applications 
in cancer cell biology, drug discovery [11] and prediction 
of drug response in patients. This method was shown to 
be effective in different cancer entities, including lung 
cancer [12, 13]. This 3D culture model is able to mimic 
tumor biology, tumor microenvironment, cell-cell and cell-
extracellular matrix interactions similar to in vivo tumors.
This study shall give a comparative analysis on the 
most frequently used non-genetic lung cancer models: 
the (I) Urethane-induced tumor model and the (II) cell 
line induced tumor models through intravenous or 
subcutaneous tumor cell injection and the (III) ex vivo/in 
vitro 3D primary cell culture model.
RESULTS
Urethane induced lung adenocarcinoma model
Twenty weeks after Urethane administration, we 
found heterogeneously developed tumor nodules within 
the lungs of mice (macroscopy Figure 1A, histology in 
Figure 1B). The tumor size and the count of tumor nodules 
were significantly higher in the BALB/c mouse strain 
than in the C57BL/6 mouse strain (Figure 1C and 1D). 
Three times of Urethane injection induced significantly 
more tumor nodules than one time injection in both mouse 
strains (Figure 1D) in spite of 0% mortality and morbidity 
with 100% tumor incidence rate. Interestingly, Tertiary 
lymphoid organs (TLOs) were exclusively found in the 
Urethane-induced tumor model compared to other models 
(microscopy in Figure 2A-2F) with a significant correlation 
of TLO incidence and the number of tumor nodules within 
the lung (Figure 2G). The location of TLO was in either 
alveolar (Figure 2A) or perivascular (Figure 2B) region 
with immune compositions of CD4+ T-cells (Figure 2C), 
CD8+ T-cells (Figure 2D), and macrophages (Figure 2E).
Cell line induced lung cancer model via 
intravenous injection of LLC
Intravenously (i.v.) injected LLC cell line to 
syngeneic C57BL/6 mice developed orthotopic lung 
cancer in two weeks (macroscopy Figure 3A, histology 
Figure 3B). The weight of lungs with i.v. induced tumor 
was significantly heavier compared to the control group 
(Figure 3C). The tumor incidence by i.v. injection of LLC 
cell line reached 100%, in which nodules were diffusely 
distributed throughout the lung. Unlike other models, this 
model has a mortality rate of 60% with severe pleural 
effusion when extending the experiment to four weeks 
(Figure 3D).
Cell line induced lung cancer model via 
subcutaneous injection of LLC
The tumor incidence rate with LLC s.c. injection 
reached 100% without mortality (macroscopy Figure 4A, 
histology Figure 4B). However, the morbidity of tumor 
ulceration was associated with the location of tumor cell 
injection. Tumors developed on the neck area caused 
a high rate of skin ulceration (macroscopy Figure 4C; 
40% skin ulcerations after 15 days after injection, 80% 
ulcerations after twenty days after injection) (Figure 4D). 
Injections into the back area did not show a significant 
morbidity up to twenty days after inoculation (Figure 
4D). Alternative assessment of s.c. tumor growth was 
performed by using caliper (Figure 4E) for four weeks 
after injection. Three dimensional s.c. tumor volume of 
each mouse is presented in Figure 4E.
Ex vivo 3D tumor culture model
Single cell suspension of tumor cells obtained from 
the s.c. - induced tumor model formed spheroids three 
days after seeding in a 3D culture condition (Figure 5A). 
The size of the formed spheroids significantly increased 
seven days after seeding compared to three days after 
seeding (Figure 5B, and 5C) which was closely related 
with the degree of proliferation (Ki-67) (Figure 5D).
Comparison among models
All in vivo models of lung cancer consistently 
developed a comparable tumor with an incidence rate 
of 100%. The induction period of the Urethane-induced 
tumor was significantly longer than in other models 
(20 weeks v.s. 2 weeks respectively). However, TLOs 
were only found in the Urethane-induced tumor model. 
The immunohistological analysis (microscopy Figure 
6A and 6B) revealed no significant count difference of 
infiltrated immune cells although CD4+ cells were found 
in higher numbers in the Urethane model. The 3D cell 
culture model showed fewer immune cells expressed in 
the spheroids after three days of culturing (Figure 6A 
and 6B). Tumor cells proliferated in all in vivo models 
consistently while tumor cells in spheroids of 3D culture 
model showed less proliferation. Table 1. provides a 
summary of the characteristics of the discussed models. 
We also compared the stromal composition of tumor 
models (Figure 7). An endothelial cell marker, CD31 was 
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more expressed in Urethane and LLC i.v. model than s.c. 
or 3D culture model. The vWF, another endothelial cell 
protein, was weakly expressed in all models. Fibronectin, 
associated with cell adhesion and migration processes 
such as epithelial-mesenchymal transition, was expressed 
especially strong in the s.c. injection model and the 3D 
cell culture model, and less expressed in the urethane 
and i.v. injection models. Fibroblast and smooth muscle 
expressing smooth muscle actin (SMA) was found in both, 
the Urethane model and the LLC i.v. injection model.
DISCUSSION
We here compared three different preclinical 
lung cancer models, (I) the Urethane-induced primary 
lung cancer model, (II) the cell line-induced tumor 
model trough i.v. or s.c. injection and (III) the ex vivo 
3D culture model of primary lung cancer. We compared 
these models with regard to tumor incidence, the 
duration of tumor induction and the composition of the 
immunohistological composition of the induced tumors. 
With the advent of the immune checkpoint inhibitors 
and the chimeric antigen receptor (CAR) T cells, cancer 
immunotherapies gain increased importance [14]. In the 
light of these emerging therapeutics, the characterization 
of relevant immune cells among most commonly used 
non-genetic mouse tumor models could be of help to 
optimize immunotherapy.
Urethane is used as a tumor-inducing agent in 
animal models, typically in inbred mice with a high 
susceptibility to spontaneous tumorigenesis. In contrast to 
the i.v. and s.c.-cell line injection models, the Urethane 
Figure 1: Representative macroscopic pictures (A) and H/E stains (picture was taken at x200 magnification) (B) of Urethane-induced 
tumor model. * indicates tumor nodule induced by intraperitoneal (i.p.) injection of Urethane. The nodules were found to be significantly 
larger in the BALB/c strain than in C57BL/6 (BALB/c: mean 1042μm2, C57BL/6: mean 199μm2; n=10 each group) (C). Three injections 
of Urethane in one week developed significantly more nodules in BALB/c and C57BL/6 mice (BALB/c: mean 3 nodules in 1x injection 
of Urethane, mean 7 nodules in 3x injection; C57BL/6: mean 0 nodules in 1x injection of Urethane, mean 2 nodules in 3x injection; n=20 
each group) (D). *p<0.05 and **p<0.01.
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model takes more time for the development of tumors. 
However, this model provides a high tumor incidence rate 
and a low morbidity and mortality rate and was therefore 
considered a reliable tumor model. Moreover, up to 91% 
of the Urethane-induced mouse adenocarcinomas are 
bearing an activating mutations in the Kras oncogene 
Figure 2: Features of Urethane induced lung cancer model. Tertiary lymphoid organ was found in Urethane injected mouse lungs. 
It was heterogeneously located in alveolar (A) and/or perivascular regions (B). Immunohistochemistry showed infiltrated immune cells 
expressing CD4 (C), CD8 (D), F4/80 (E), and Ki-67 (F) (x200 magnification). The incidence of TLO significantly correlated (p=0.0015) 
with the number of tumor nodules in the lung (G).
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which is a major advantage of the Urethane-induced tumor 
model [8]. Activating Kras mutations belong to the most 
frequent mutations in lung adenocarcinomas and can be 
found in about 17% of all lung adenocarcinoma patients. 
Up to now, there is no therapeutic intervention to target 
Kras mutation in non-small cell lung cancer (NSCLC). 
By using genomic profiling, Kras subgroups with varying 
therapeutic vulnerability have been identified and different 
therapeutic modalities are now tested on these subgroups 
[15]. Since the Kras mutation is an important property of 
the Urethane-induced tumor model, this model could be 
crucial in preclinical experiments.
TLO forms as a lymphatic tissue in the conditions 
of chronic inflammation, e.g. in autoimmune diseases, 
chronic infections or cancer and function as local sites for 
priming of the adaptive immune system (T and B cells) 
[16, 17]. The incidence of TLO is a prognostic marker 
for a better outcome in different cancer types [18–20]. 
Therefore, Urethane-induced tumor model comprises 
a high clinical relevance. Another carcinogen in-use is 
Diethylnitrosamine (DEN) which has the potential to 
induce tumors in various organs including the lung [21, 
22]. We found in preliminary mouse experiments the 
tumor incidence rate to be significantly lower (3/10 mice) 
than in Urethane treated mice.
The s.c. cell line injection model was a reliable 
model with simple administration of tumor cells and 
conveniently accessible tumor nodules within the injection 
area. As the tumor nodules can easily be removed from 
beneath the skin, this model allows the sole analysis of 
Figure 3: Representative macroscopic pictures (A) and H/E stains (x200 magnification) (B) of intravenous injection of tumor cell 
line model. T indicates tumor, L indicates lung, and H indicates heart. Intravenous injected LLC cell line developed diffuse lung cancer 
nodules two weeks after injection (n=10). Lungs (n=4) in tumor cell line-injected mice were significantly heavier two weeks after injection 
compared to control group (n=3) (C). Pleural effusion-associated morbidity and mortality of LLC i.v. injected mice was observed in 60% 
of total (n=5) (D). ***p<0.001.
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the tumor tissue without the biasing adjacent lung or soft 
tissue. We found the morbidity rate highly depending on 
the area of injection, with a significant increased morbidity 
(skin ulcerations) in extended experiments when the cell 
line was injected into the neck area compared to injections 
into back area. This phenomenon was not demonstrated 
Figure 4: Representative macroscopic pictures (A) and H/E stains (x200 magnification) (B) of subcutaneous injection of tumor cell line 
model. Significant more skin ulcerations (n=12) (C) were found after subcutaneous tumor cell injection in neck compared to subcutaneous 
injections into back area (n=8) (D). Exponential tumor growth developed by LLC s.c. injection was presented as mm3 volume measured by 
caliper (n=4) (E). ****p<0.0001.
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elsewhere. Therefore, if experiments are planned for a 
longer duration, cell line injections into neck area should 
be avoided.
In the i.v. injection model, orthotopic tumors were 
found homogenously distributed in the lung. Orthotopic 
tumor growth allows experiments on tumors in the 
clinically relevant site and reflects the physiologic setting 
in a more convenient way [23]. Since the surgical access 
to the inferior vena cava has to be carried out through 
the peritoneal cavity, this method is more challenging 
and insulting than the other models. In terms of tumor 
induction time and incidence rate, the i.v. injection model 
was comparable with the other s.c. injection models. 
However, in contrast to the other models, i.v. model 
showed a higher morbidity rate with complications such 
as pleural effusions or metastasis into the pleural cavity. 
However, this applies to the LLC cell line which we 
injected in this tumor model, other cell lines might have 
a different behavior with regard to side effects, but also 
to growth rate, induction period or tumor incidence rate.
We compared the immunohistological results of 
the in vivo mouse models with an in vitro model, the 
3D primary cell culture model. As a reliable alternative 
to the in vivo models, the 3D primary cell culture 
model proofed to be a feasible model in preclinical 
research [24, 25] as well as in the characterization of an 
individual tumor [26–30]. With their more physiological 
tumor microenvironment, cell-matrix and cell-cell 
communications and gradients of oxygen, nutrients 
and growth factors, the 3D cell culture models feature 
a more sophisticated method for ex vivo/in vitro studies 
than the conventional 2D cell culture models [12, 29]. 
While T cells were consistently expressed in the other 
models, most prominent in the i.v. injection of LLC, the 
immunohistological examination of 3D cell culture model 
showed CD4+ and CD8+ cells to be almost absent in tumor 
spheroids built from cells of s.c.-LLC injection tumor.
With regard to the shortcomings of this study, we 
emphasize that we did not consider the patient derived 
xenograft model, reflecting the human gene expression 
Figure 5: Representative pictures of H/E stains (x400 magnification) (A) of 3D primary tumor cell culture model after three and seven 
days of culturing (B). Spheroids seven days after seeding were significantly larger in site compared to three days after seeding (n=4 each 
group) (C). Spheroids contained significantly more proliferating cells (Ki-67+ cells) three days after seeding compared to seven days after 
seeding (n=4 each group) (D). *p<0.05 and ***p<0.001.
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Figure 6: Immunohistological analysis of animal lung cancer models (x200 magnification for Urethane, LLC i.v. and 
LLC s.c. models and at x400 magnification for 3D primary cell culture model). (A) Urethane, LLC i.v., LLC s.c. induced 
lung tumor samples and 3D primary cell culture model spheroids were stained by antibodies of CD4, CD8, F4/80, NKp46, and Ki-67. (B) 
Comparison of microscopically counting of infiltrated CD4+, CD8+, F4/80+ and NKp46+ cells among models. Mean CD4+ cells per HPF at 
x200 magnification: 54 in Urethane model (n=6), 11 in LLC i.v. (n=11), 10 in LLC s.c. (n=7), 0 in 3D (n=4). Mean CD8+ cells per HPF at 
x200 magnification: 15 in Urethane model (n=7), 18 in LLC i.v. (n=9), 10 in LLC s.c. (n=8), 0 in 3D (n=4). Mean F4/80+ cells per HPF at 
x200 magnification: 36 in Urethane model (n=8), 20 in LLC i.v. (n=13), 34 in LLC s.c. (n=9), 4 in 3D (n=4). Mean NKp46+ cells per HPF 
at x200 magnification: 3 in Urethane model (n=7), 1 in LLC i.v. (n=13), 6 in LLC s.c. (n=4), 0 in 3D (n=4). p>0.05; HPF: high-power field.
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Table 1: Comparison of model characteristics
Model Incidence (%)
Induction 
period 
(weeks)
Morbidity 
(%)
Mortality 
(%) CD4 CD8 F4/80 NKp46 TLO
Urethane-injection 
model (orthotopic) 100 20 0 0 ++ ++ +++ + A
Intravenous tumor 
cell line injection 
model (orthotopic)
100 2
100 
(Pleural 
effusion)
0 (2w) 
60 (4w) + ++ ++ + NA
Subcutaneous 
tumor cell line 
injection model 
(heterotopic)
100 2 0 (2w) 95 (3w) 0 + ++ +++ ++ NA
3D cell culture 
model (ex vivo) NA NA NA NA - - + - NA
Abbreviations: A: available; NA: not available; w: weeks; -: no positive cells; +: few present; ++: intermediately present; 
+++: abundantly present.
Figure 7: Immunohistological analysis of animal lung cancer models (x200 magnification for Urethane, LLC i.v., 
LLC s.c. and for 3D primary cell culture models): Urethane, LLC i.v., LLC s.c. induced lung tumor samples and 3D 
primary cell culture model spheroids were stained by antibodies of CD31, Fibronectin, SMA and vWF.
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status, the drug response and the tumor architecture of the 
patients’ tumor cells [31]. Another drawback is the fact 
that immune cells were virtually absent three days after 
culturing and the proliferation arrested after seven days 
of culturing in the spheroids of our 3D primary culture 
model.
In conclusion, the different discussed lung tumor 
mouse models showed a similar high tumor incidence 
rate after injection of tumor cells, but differed in terms 
of induction time, morbidity and mortality. Though 
there were tendencies in immunohistochemical staining 
of immune cells, no clear significant difference in 
the count of tumor infiltrating immune cells could be 
found. It can therefore be expected that when testing for 
immunotherapies in these models, results on them can 
be considered to be comparable. However, TLOs could 
exclusively found in the Urethane-induced tumor model 
which should be considered in experiments involving the 
adaptive immune system.
MATERIALS AND METHODS
Animals and animal care
Male wild type mice (BALB/c and C57BL/6, 
Charles River, Germany) were used for all experiments. 
Animals were fed a standard laboratory diet with water 
ad libitum and were kept under constant environmental 
conditions in the Biological Central Labor, University 
Hospital Zurich. All experimental procedures were 
approved by the veterinary office of the canton of Zurich 
(License number: ZH83/14) and performed in accordance 
with the institutional animal care guidelines.
Tumor cell line
Lewis lung carcinoma (LLC) cell line was purchased 
from American Type Culture Collection (Manassas, USA). 
The cell line was stored at early passages (<3) in liquid 
nitrogen and were used in the experiments for no more 
than 6 months. The cell line was cultivated in DMEM 
containing 10 % FBS and penicillin/streptomycin within 
5 % CO2 chamber.
Urethane-induced tumor model
Two experimental groups of C57BL/6 mice were 
formed: one group received one intraperitoneal (i.p.) 
injection with 1 mg/g Urethane (Sigma, Germany); the 
other group received three i.p. injections with 1 mg/g 
Urethane in one week. Twenty weeks after injection, the 
animals were sacrificed by exsanguination, followed by 
flushing with saline and en bloc resection of the thoracic 
organs including bilateral lungs, heart, and thymus. The 
whole lung was fixed in formalin and embedded in paraffin 
for counting tumor nodules and immunohistochemistry 
(IHC).
Cell line-induced tumor model via intravenous 
injection of LLC
LLC cells (0.25 x 106 cells/mouse) were injected 
into the inferior vena cava of C57BL/6 mice after midline 
laparotomy under isoflurane anesthesia. Under the control 
of the vital signs (e.g. respiration rate, organ color) and 
integrity of the vessel at the injection site, the abdominal 
wall was closed by a running suture. Two weeks after 
tumor cell injection, total lungs were weighted. Animals 
were sacrificed by exsanguination followed by flushing 
with saline and en bloc resection of thoracic organs 
including bilateral lungs, heart, and thymus.
Cell line induced tumor model via subcutaneous 
injection of LLC
LLC cells (1 x 106 cells/mouse) were injected under 
the skin of C57BL/6 mice (either back or neck area) within 
serum free DMEM. Two weeks after tumor cell injection, 
the tumor was isolated from skin and weighed after 
exsanguination according to the experimental time points. 
The tumor mass was kept in formalin and embedded in 
paraffin for IHC.
Ex vivo 3D primary tumor cell culture model
The primary tumor developed by subcutaneous (s.c.) 
injection of LLC cell line was harvested two weeks after 
inoculation and was digested by collagenase. Chopped 
tumor tissue was digested in buffer-containing collagenase 
II for one hour and passed through 30um pore size mesh. 
After washing, single cell suspension was placed with 
ACL-4 media. The cell suspension of the primary tumor 
was counted by a TC-20 automatic cell counter (Biorad) 
and placed onto 3D culture plates including a Perfecta 
hanging drop plate (Sigma, Germany) using 104 cells. The 
media was changed daily. After five days, tumors were 
fixed in 4% paraformaldehyde and fixed with Histogel and 
paraffin for IHC.
Histology and immunohistochemistry
Formalin fixed and paraffin embedded samples were 
stained by antibodies against Ki-67 (Abcam, UK), CD4 
(eBioscience, USA), CD8 (eBioscience, USA), F4/80 
(BMA Biomedicals, Switzerland), NKp46 (R&D Systems, 
USA), CD31 (Abcam, UK), fibronectin (Millipore, 
Switzerland), smooth muscle actin (SMA, Dako, USA), 
and von Willebrand Factor (vWF, Dako USA). The 
evaluation of stainings was conducted in a blind manner. 
For the microscopic assessment of Urethane-induced 
tumors, we counted tumor nodules in all lungs embedded 
in a horizontal direction on paraffin. The size of tumor 
nodules was measured at x40 magnification with a 
microscope (Leica, Wetzlar, Germany) and extrapolated 
into actual size. TLOs were counted in all lungs. TLOs 
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are lymphatic tissues postnatally induced through 
inflammation or infection in non-lymphoid organs and 
functioning as sites for priming of the adaptive immune 
system (T and B cells) [16].
Statistical analysis
Data were presented as means ± SD. Groups were 
compared with the Student t-test for unpaired samples 
using Prism 4.0 (GraphPad Software, San Diego, CA, 
USA). A two-sided p-value <0.05 was considered as 
statistically significant.
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